HARRY BROWN: Open Payments
NPI 1144877978 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,868 in 85 payments from 17 companies in 2025. Trend: 2023 $1,850 · 2024 $1,455 · 2025 $1,868
Food & beverage: $1,868
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $274 |
| Axsome Therapeutics, Inc. | 4 | $257 |
| Janssen Pharmaceuticals, Inc | 11 | $238 |
| E.R. Squibb & Sons, L.L.C. | 14 | $235 |
| Otsuka America Pharmaceutical, Inc. | 8 | $183 |
| Alkermes, Inc. | 8 | $168 |
| Neurocrine BioSciences, Inc. | 6 | $147 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Merck Sharp & Dohme LLC | 3 | $66 |
| Corium, LLC | 4 | $61 |
Products named: VRAYLAR, Auvelity, COBENFY, SPRAVATO, INGREZZA, REXULTI, ARISTADA, INVEGA.
Industry payments across LA — which companies pay providers there.
